SMT201400053B - Forme farmaceutiche orali di bendamustina - Google Patents

Forme farmaceutiche orali di bendamustina

Info

Publication number
SMT201400053B
SMT201400053B SM201400053T SM201400053T SMT201400053B SM T201400053 B SMT201400053 B SM T201400053B SM 201400053 T SM201400053 T SM 201400053T SM 201400053 T SM201400053 T SM 201400053T SM T201400053 B SMT201400053 B SM T201400053B
Authority
SM
San Marino
Prior art keywords
bendamustine
oral pharmaceutical
pharmaceutical forms
forms
oral
Prior art date
Application number
SM201400053T
Other languages
English (en)
Inventor
Jeffrey Colledge
Margaretha Olthoff
Original Assignee
Astellas Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40588059&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201400053(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Deutschland Gmbh filed Critical Astellas Deutschland Gmbh
Publication of SMT201400053B publication Critical patent/SMT201400053B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SM201400053T 2008-12-03 2014-04-22 Forme farmaceutiche orali di bendamustina SMT201400053B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08075915 2008-12-03
PCT/EP2009/008857 WO2010063493A1 (en) 2008-12-03 2009-12-03 Oral dosage forms of bendamustine

Publications (1)

Publication Number Publication Date
SMT201400053B true SMT201400053B (it) 2014-07-07

Family

ID=40588059

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201400053T SMT201400053B (it) 2008-12-03 2014-04-22 Forme farmaceutiche orali di bendamustina

Country Status (25)

Country Link
US (4) US20120003305A1 (it)
EP (1) EP2367542B1 (it)
JP (1) JP5778037B2 (it)
KR (1) KR101688038B1 (it)
CN (2) CN102281871A (it)
AU (1) AU2009321745B2 (it)
BR (1) BRPI0922806B8 (it)
CA (1) CA2745525A1 (it)
CO (1) CO6400183A2 (it)
CY (1) CY1114977T1 (it)
DK (1) DK2367542T3 (it)
EA (1) EA020354B1 (it)
ES (1) ES2451540T3 (it)
HR (1) HRP20140204T1 (it)
IL (1) IL213270A (it)
MX (1) MX2011005643A (it)
NZ (1) NZ592970A (it)
PL (1) PL2367542T3 (it)
PT (1) PT2367542E (it)
RS (1) RS53201B (it)
SI (1) SI2367542T1 (it)
SM (1) SMT201400053B (it)
UA (1) UA102120C2 (it)
WO (1) WO2010063493A1 (it)
ZA (1) ZA201103791B (it)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3659B1 (ar) * 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
JO3587B1 (ar) * 2010-06-02 2020-07-05 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم
CN102375044B (zh) * 2010-08-18 2015-04-08 重庆华邦胜凯制药有限公司 一种盐酸苯达莫司汀中间体z6有关物质的分析方法
ES2613838T3 (es) * 2011-09-26 2017-05-26 Fresenius Kabi Oncology Ltd Un procedimiento mejorado para la preparación de hidrocloruro de bendamustina
PT3091029T (pt) * 2011-10-31 2023-02-03 Hoffmann La Roche Formulações de anticorpos anti-il13
EP2641592A1 (en) 2012-03-23 2013-09-25 Salmon Pharma GmbH Pharmaceutical formulation comprising bendamustine
EP2656843B1 (en) 2012-04-26 2015-03-18 Helmut Schickaneder Esters of bendamustine and related compounds, and medical use thereof
TWI598341B (zh) * 2012-11-12 2017-09-11 伊格尼塔公司 苯達莫司汀衍生物及其使用方法
MX362032B (es) 2013-03-12 2019-01-04 Cephalon Inc Formulaciones nanoparticuladas y macroparticuladas.
JP2016153374A (ja) * 2013-06-25 2016-08-25 シンバイオ製薬株式会社 炎症性疾患を治療又は予防するための医薬組成物
EP3043648B1 (en) 2013-08-27 2023-09-20 Vasilios VOUDOURIS Bendamustine pharmaceutical compositions
EP3691637A1 (en) 2017-10-05 2020-08-12 TUBE Pharmaceuticals GmbH Oral bendamustine formulations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US132502A (en) * 1872-10-22 Improvement in machines for removing snow from railroads
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US20030105141A1 (en) * 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
CN101933923A (zh) 2004-11-05 2011-01-05 赛福伦公司 癌症治疗
CN101052396A (zh) * 2004-11-05 2007-10-10 赛福伦公司 癌症治疗
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
UA94036C2 (ru) * 2005-01-14 2011-04-11 Сефалон, Инк. Фармацевтическая композиция бендамустина, предназначенная для лиофилизации
CN101028249A (zh) * 2007-04-12 2007-09-05 济南康泉医药科技有限公司 一种含新生血管抑制剂及烷化剂的抗癌组合物
CN101045058A (zh) * 2007-04-28 2007-10-03 济南帅华医药科技有限公司 一种含烷化剂及激素类药物的抗癌组合物
CN101084876A (zh) * 2007-07-11 2007-12-12 济南康泉医药科技有限公司 一种含苯达莫司汀的抗癌组合物
US20090130198A1 (en) * 2007-11-21 2009-05-21 Innopharmax Inc. Pharmaceutical composition with enhanced bioavailability
US8349353B2 (en) * 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders

Also Published As

Publication number Publication date
US20150335588A1 (en) 2015-11-26
IL213270A (en) 2017-05-29
CY1114977T1 (el) 2016-12-14
PT2367542E (pt) 2014-03-10
ZA201103791B (en) 2012-07-25
PL2367542T3 (pl) 2014-05-30
AU2009321745B2 (en) 2016-06-23
NZ592970A (en) 2013-05-31
EP2367542A1 (en) 2011-09-28
RS53201B (en) 2014-06-30
CA2745525A1 (en) 2010-06-10
WO2010063493A1 (en) 2010-06-10
BRPI0922806B8 (pt) 2021-05-25
BRPI0922806A2 (pt) 2015-12-22
CN105363037B (zh) 2019-02-05
DK2367542T3 (da) 2014-03-10
UA102120C2 (ru) 2013-06-10
SI2367542T1 (sl) 2014-05-30
EA020354B1 (ru) 2014-10-30
CN105363037A (zh) 2016-03-02
US20120003305A1 (en) 2012-01-05
AU2009321745A1 (en) 2011-06-23
BRPI0922806B1 (pt) 2020-03-03
US20140018334A1 (en) 2014-01-16
US20170095452A1 (en) 2017-04-06
JP2012510484A (ja) 2012-05-10
CN102281871A (zh) 2011-12-14
JP5778037B2 (ja) 2015-09-16
MX2011005643A (es) 2011-09-27
ES2451540T3 (es) 2014-03-27
KR101688038B1 (ko) 2016-12-20
EP2367542B1 (en) 2014-01-01
US10543196B2 (en) 2020-01-28
HRP20140204T1 (hr) 2014-04-11
CO6400183A2 (es) 2012-03-15
IL213270A0 (en) 2011-07-31
EA201190011A1 (ru) 2012-02-28
KR20110102393A (ko) 2011-09-16

Similar Documents

Publication Publication Date Title
SMT201400053B (it) Forme farmaceutiche orali di bendamustina
SMT201700095B (is) Composizioni farmaceutiche per inalazione
HRP20171421T1 (hr) Kruti oblici doziranja bendamustina
BRPI0920521A2 (pt) combinação farmacêutica
DK3061445T3 (da) Højkoncentrerede farmaceutiske formuleringer
SMT201400069B (it) Formulazione farmaceutica
DK2285413T3 (da) Farmaceutisk sammensætning
BRPI0921654A2 (pt) formulação farmacêutica
DK2391349T3 (da) Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
DK2391351T3 (da) Farmaceutisk sammensætning omfattende 2-oxo-1-pyrrolidinderivater
BRPI0921313A2 (pt) composição farmaucêutica
DK2271618T3 (da) Farmaceutiske forbindelser
BRPI0912171A2 (pt) composição farmacêutica
BRPI0818702A2 (pt) Formulação farmacêutica de ácido clavulânico
BRPI1013037A2 (pt) "solução farmacêutica oral de telmisartan"
BRPI0912656A2 (pt) formulação farmacêutica sólida
CU23884B1 (es) Derivados de dibenzotiazepina
BRPI0823402A2 (pt) Formulações farmacêuticas de olmesartan
IT1390848B1 (it) Composti farmaceutici
SMT201500123B (it) Dosaggio unitario di apadenoson
BRPI0921301A2 (pt) composição farmacêutica
BRPI0923379A2 (pt) Formulação para administração por via transmucosa oral de setronas
BRPI1008983A2 (pt) formulação farmacêutica
IT1393245B1 (it) Forme farmaceutiche per il rilascio tempo-specifico di farmaci
FI20080013A0 (fi) Uudet farmaseuttiset formulaatiot